DE602005024021D1 - GEN ANLN IN VERBINDUNG MIT NICHT-KLEINZELLIGEM LUNGENKREBS UND SEINE WECHSELWIRKUNGEN MIT RhoA - Google Patents

GEN ANLN IN VERBINDUNG MIT NICHT-KLEINZELLIGEM LUNGENKREBS UND SEINE WECHSELWIRKUNGEN MIT RhoA

Info

Publication number
DE602005024021D1
DE602005024021D1 DE602005024021T DE602005024021T DE602005024021D1 DE 602005024021 D1 DE602005024021 D1 DE 602005024021D1 DE 602005024021 T DE602005024021 T DE 602005024021T DE 602005024021 T DE602005024021 T DE 602005024021T DE 602005024021 D1 DE602005024021 D1 DE 602005024021D1
Authority
DE
Germany
Prior art keywords
cancer
anln
rhoa
interaction
small cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005024021T
Other languages
German (de)
English (en)
Inventor
Yusuke Nakamura
Yataro Daigo
Shuichi Nakatsuru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of DE602005024021D1 publication Critical patent/DE602005024021D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602005024021T 2004-08-10 2005-08-09 GEN ANLN IN VERBINDUNG MIT NICHT-KLEINZELLIGEM LUNGENKREBS UND SEINE WECHSELWIRKUNGEN MIT RhoA Expired - Lifetime DE602005024021D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60056104P 2004-08-10 2004-08-10
PCT/JP2005/014887 WO2006016697A1 (en) 2004-08-10 2005-08-09 Non-small cell lung cancer-related gene, anln, and its interactions with rhoa

Publications (1)

Publication Number Publication Date
DE602005024021D1 true DE602005024021D1 (de) 2010-11-18

Family

ID=35355888

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005024021T Expired - Lifetime DE602005024021D1 (de) 2004-08-10 2005-08-09 GEN ANLN IN VERBINDUNG MIT NICHT-KLEINZELLIGEM LUNGENKREBS UND SEINE WECHSELWIRKUNGEN MIT RhoA

Country Status (6)

Country Link
US (1) US20090297500A1 (https=)
EP (1) EP1787122B1 (https=)
JP (1) JP4874234B2 (https=)
AT (1) ATE483979T1 (https=)
DE (1) DE602005024021D1 (https=)
WO (1) WO2006016697A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8131476B2 (en) 2006-08-07 2012-03-06 General Electric Company System and method for co-registering multi-channel images of a tissue micro array
US8060348B2 (en) 2006-08-07 2011-11-15 General Electric Company Systems for analyzing tissue samples
WO2008063413A2 (en) 2006-11-13 2008-05-29 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of lung cancer
JP2010523081A (ja) * 2007-03-30 2010-07-15 オンコセラピー・サイエンス株式会社 Ｃｄｃａ８−ａｕｒｋｂ複合体を標的とするスクリーニング方法およびｎｓｃｌｃの治療方法
EP2161577A1 (en) * 2008-09-01 2010-03-10 Atlas Antibodies AB ANLN protein
WO2012006632A2 (en) 2010-07-09 2012-01-12 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US9125899B1 (en) 2010-06-17 2015-09-08 Stc.Unm Modulators of GTPases and their use
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
JP6127972B2 (ja) 2011-09-09 2017-05-17 コニカミノルタ株式会社 組織染色方法
CA3064363C (en) * 2011-10-24 2022-05-17 Somalogic, Inc. Non-small cell lung cancer biomarkers and uses thereof
JP5806168B2 (ja) * 2012-06-19 2015-11-10 国立大学法人 岡山大学 抗浸潤薬の新規スクリーニング法
WO2014078700A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US10870854B2 (en) 2016-06-09 2020-12-22 The Board Of Regents Of The University Of Texas System Inhibitory RNA-based therapeutics targeting ANLN for cancer treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
EP1620573A4 (en) * 2003-04-15 2006-12-20 Avalon Pharmaceuticals DETERMINATION OF CANCER-ASSOCIATED GENES AND THERAPEUTIC OBJECTS USING MOLECULAR CYTOGENETIC PROCEDURES

Also Published As

Publication number Publication date
EP1787122A1 (en) 2007-05-23
ATE483979T1 (de) 2010-10-15
EP1787122B1 (en) 2010-10-06
US20090297500A1 (en) 2009-12-03
JP4874234B2 (ja) 2012-02-15
WO2006016697A1 (en) 2006-02-16
JP2008510126A (ja) 2008-04-03

Similar Documents

Publication Publication Date Title
DE602005024021D1 (de) GEN ANLN IN VERBINDUNG MIT NICHT-KLEINZELLIGEM LUNGENKREBS UND SEINE WECHSELWIRKUNGEN MIT RhoA
BRPI0611670A2 (pt) método para o tratamento ou prevenção de câncer em um indivíduo
IL258880A (en) Diarylhydantoin compounds
MX2020012731A (es) Inhibidores de kras g12c y metodos para su uso.
WO2020239895A3 (en) Detection of colorectal cancer
CY1118612T1 (el) Μεθοδοι και χημικες συνθεσεις για την θεραπευτικη αντιμετωπιση των εμμενουσων λοιμωξεων και του καρκινου μεσω αναστολης της οδου προγραμματισμενου κυτταρικου θανατου 1 (pd-1)
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
CY1108092T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου με την αναστολη της κινασης aurora
ATE547102T1 (de) Carbolin-derivate zur behandlung von krebs
ATE404574T1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
DK1951759T3 (da) Anti-EGFR-antistoffer
MX2007006640A (es) Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
ATE554769T1 (de) Neuromuskuläre blocker mit mittlerer dauer und antagonisten advon
WO2008011519A3 (en) Amigo-2 inhibitors for treating, diagnosing or detecting cancer
WO2007141280A3 (en) Proteins
WO2007120787A3 (en) Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression
EP1774043A4 (en) COMPOSITIONS, KITS AND METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER
ATE422162T1 (de) Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen
ATE502025T1 (de) Arylcarboxamide und ihre verwendung als antitumormittel
TW200716132A (en) Novel chemical compounds
WO2006086772A3 (en) DIAGNOSING AND TREATING CANCER USING β-CATENIN SPLICE VARIANTS
TW200605885A (en) Multicyclic lonidamine analogs
WO2023004342A3 (en) Methods for identifying adar1 inhibitors, and compositions and methods of use in treating cancer
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung